Search results for "Beclomethasone"

showing 10 items of 23 documents

Predicting Lung Deposition of Extrafine Inhaled Corticosteroid-Containing Fixed Combinations in Patients with Chronic Obstructive Pulmonary Disease U…

2021

Background: Functional respiratory imaging (FRI) is a computational fluid dynamics-based technique using three-dimensional models of human lungs and formulation profiles to simulate aerosol deposition. Methods: FRI was used to evaluate lung deposition of extrafine beclomethasone dipropionate (BDP)/formoterol fumarate (FF)/glycopyrronium bromide (GB) and extrafine BDP/FF delivered through pressurized metered dose inhalers and to compare results with reference gamma scintigraphy data. FRI combined high-resolution computed tomography scans of 20 patients with moderate-to-severe chronic obstructive pulmonary disease (mean forced expiratory volume in 1 second 42% predicted) with in silico comput…

PathologyRespiratory SystemPharmaceutical ScienceINHALATION030226 pharmacology & pharmacyPulmonary Disease Chronic Obstructive0302 clinical medicineAdrenal Cortex HormonesFormoterol FumaratePharmacology (medical)1102 Cardiorespiratory Medicine and Haematologycombination drugLungBRONCHODILATOROriginal Researchlung depositionBeclomethasonerespiratory systemDrug CombinationsTreatment OutcomeCorticosteroid1115 Pharmacology and Pharmaceutical SciencesPMDILife Sciences & BiomedicineCombination drugPulmonary and Respiratory Medicinemedicine.medical_specialtyLung depositionextrafinemedicine.drug_classIn silicoPulmonary diseaseSettore MED/10 - Malattie Dell'Apparato Respiratorioinhaled corticosteroid03 medical and health sciencespressurized metered-dose inhalerAdministration InhalationmedicineHumansIn patientComputer SimulationSMALL AIRWAYScombination drug extrafine functional respiratory imaging inhaled corticosteroid lung deposition pressurized metered-dose inhalerScience & TechnologyRespiratory imagingbusiness.industryDYSFUNCTION030228 respiratory systemASTHMAfunctional respiratory imagingbusiness
researchProduct

Fractional exhaled nitric oxide as a predictor of response to inhaled corticosteroids in patients with non-specific respiratory symptoms and insignif…

2017

Chronic non-specific respiratory symptoms are difficult to manage. This trial aimed to evaluate the association between baseline fractional exhaled nitric oxide (FeNO) and the response to inhaled corticosteroids in patients with non-specific respiratory symptoms.In this double-blind randomised placebo-controlled trial, we enrolled undiagnosed patients, aged 18-80 years, with cough, wheeze, or dyspnoea and less than 20% bronchodilator reversibility across 26 primary care centres and hospitals in the UK and Singapore. Patients were assessed for 2 weeks before being randomly assigned (1:1) to 4 weeks of treatment with extrafine inhaled corticosteroids (QVAR 80 μg, two puffs twice per day, equi…

Pulmonary and Respiratory MedicineAdultMalePediatricsmedicine.medical_specialtyAdolescentmedicine.drug_classPlaceboNitric Oxidelaw.invention03 medical and health sciencesYoung Adult0302 clinical medicineRandomized controlled trialDouble-Blind MethodlawBronchodilatorWheezeInternal medicineAdministration InhalationmedicineHumans030212 general & internal medicineAnti-Asthmatic AgentsRespiratory systemAdverse effectAgedAged 80 and overInhalationbusiness.industryBeclomethasoneMiddle Agedrespiratory systemRespiration Disordersrespiratory tract diseasesTreatment Outcome030228 respiratory systemExhalationExhaled nitric oxideFemaleHuman medicinemedicine.symptombusiness
researchProduct

Effect of beclomethasone dipropionate on the bronchial responsiveness to propranolol in asthmatics.

1990

The effect of four weeks of treatment with beclomethasone dipropionate (BDP, 500 micrograms twice daily) on the bronchial responsiveness to propranolol was examined in 16 patients with mild asthma in a placebo-controlled, double-blind crossover study. Propranolol was inhaled in doubling concentrations and the results were expressed as the cumulative dose producing a 20 percent fall in FEV1 (PC20). After four weeks of treatment with BDP, the mean FEV1 increased from 82.0 percent predicted to 88.1 percent predicted. The difference was significant (p less than 0.001). Treatment with BDP did not significantly change the responsiveness to propranolol, the geometric mean PC20 being 3.17 mg/ml bef…

Pulmonary and Respiratory MedicineAdultMaleTime FactorsMild asthmaPropranololCritical Care and Intensive Care MedicineBronchial Provocation TestsRandom AllocationDouble-Blind MethodForced Expiratory VolumeAdministration InhalationmedicineAsthmatic patientHumansAsthmaBronchial SpasmCumulative dosebusiness.industryRespiratory diseaseBeclomethasonerespiratory systemmedicine.diseaseCrossover studyPropranololAsthmaAnesthesiaBronchoconstrictionFemalemedicine.symptomCardiology and Cardiovascular Medicinebusinessmedicine.drugChest
researchProduct

Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma.

2002

The ability of omalizumab, an anti-immnoglobulin-E agent, to maintain long-term disease control in patients with moderate-to-severe allergic asthma was investigated in a 24-week double-blind extension to a 28-week core trial. During the extension, 483 of the initial 546 patients were maintained on randomised treatment and the lowest sustainable dose of beclomethasone dipropionate (BDP) as established during the steroid-reduction phase of the core trial. The use of concomitant asthma medication was permitted and investigators were allowed to adjust the BDP dose or switch patients from BDP to other asthma medications if deemed necessary. More omalizumab-treated patients (33.5%) than placebo-t…

Pulmonary and Respiratory MedicineAdultMalemedicine.medical_specialtyAllergyTime FactorsAdolescentOmalizumabOmalizumabImmunoglobulin EPlaceboAntibodies Monoclonal HumanizedSeverity of Illness Indexlaw.inventionRandomized controlled trialDouble-Blind MethodlawInternal medicinemedicineHypersensitivityHumansAnti-Asthmatic AgentsAdverse effectChildAsthmaAgedbiologyDose-Response Relationship Drugbusiness.industryBeclomethasoneAntibodies MonoclonalMiddle Agedmedicine.diseaseAsthmaSurgeryAntibodies Anti-IdiotypicTreatment OutcomeConcomitantbiology.proteinFemalebusinessmedicine.drugFollow-Up StudiesThe European respiratory journal
researchProduct

65) LUNG LOCALIZATION OF AEROSOLISED BECLOMETHASONE DIPROPIONATE-LOADED NANOPARTICLES AND THEIR POSSIBLE ROLE IN ENHANCING ANTI-INFLAMMATION ACTION O…

2012

Settore CHIM/09 - Farmaceutico Tecnologico ApplicativoPOLYMERIC NANOPARTICLES BECLOMETHASONE DIPROPIONATE
researchProduct

POLYMERIC MICELLES BASED ON A PHOSPHOLIPID/ POLYASPARTAMIDIC COPOLYMER FOR BECLOMETHASONE DIPROPIONATE DELIVERY TO THE LUNGS

2010

Settore CHIM/09 - Farmaceutico Tecnologico Applicativoalphabeta-poly(N-2-hydroxyethyl)-DL-aspartamide (PHEA) 12-Distearoyl-sn-glycero-3-Phosphoethanolamine-N-[Amino(Polyethylene glycol)2000] (DSPE-PEG2000-NH2) polymeric micelles drug delivery beclomethasone dipropionate (BDP) pulmonary diseases.
researchProduct

Polymeric drug delivery micelle-like nanocarriers for pulmonary administration of beclomethasone dipropionate

2017

In this paper, the potential of novel polymeric micelles as drug delivery systems for Beclomethasone Dipropionate (BDP) administration into the lung is investigated. These nanostructures are obtained starting from α,β-poly(N-2-hydroxyethyl)-D,L-aspartamide (PHEA), which was subsequently functionalized with O-(2-aminoethyl)-O’-methylpolyethylenglycole (PEG2000), ethylenediamine (EDA) and lipoic acid (LA), obtaining PHEA-PEG2000-EDA-LA graft copolymer. Empty and drug-loaded micelles possess adequate chemical-physical characteristics for pulmonary administration such as spherical shape, slightly positive surface charge and mean size of about 200 nm. Besides, BDP-loaded micelles, obtained …

Surface PropertieAnti-Inflammatory AgentsBiocompatible MaterialsMucin permeation02 engineering and technologyPharmacology030226 pharmacology & pharmacyMicelleAntioxidantsDrug Delivery Systems0302 clinical medicineNanoparticleColloid and Surface ChemistryCopolymerDrug CarrierLungMicellesmedia_commonCell uptakeBiocompatible MaterialDrug CarriersLipoic acidThioctic AcidChemistryBeclomethasoneSurfaces and InterfacesGeneral Medicinerespiratory systemEthylenediamines021001 nanoscience & nanotechnologyPolyaspartamideAnti-Inflammatory AgentDrug deliveryPeptideAntioxidant0210 nano-technologyDrug carrierSurfaces and InterfaceHumanBiotechnologyDrugBiocompatibilitySurface PropertiesCell Survivalmedia_common.quotation_subjectEthylenediamineBronchi03 medical and health sciencesMicroscopy Electron TransmissionPolymeric micelleHumansSurface chargeParticle SizePhysical and Theoretical ChemistryEpithelial CellEthanolEpithelial CellsMicroscopy FluorescenceSettore CHIM/09 - Farmaceutico Tecnologico ApplicativoNanoparticlesNanocarriersPeptidesDrug Delivery SystemNuclear chemistrySustained releaseMicelle
researchProduct

PHEA-graft-polybutylmethacrylate copolymer microparticles for delivery of hydrophobic drugs.

2012

Abstract Polymeric microparticles encapsulating two model hydrophobic drugs, beclomethasone dipropionate (BDP) and flutamide (FLU) were prepared by using the high pressure homogenization-solvent evaporation method starting from a oil-in-water emulsion. For the preparation of polymeric microparticles a α,β-poly(N-2-hydroxyethyl)- d , l -aspartamide (PHEA) graft copolymer with comb like structure was properly synthesized via grafting from atom transfer radical polymerization (ATRP) technique, by using two subsequent synthetic steps. In the first step a polymeric multifunctional macroinitiator was obtained by the conjugation of a proper number of 2-bromoisobutyryl bromide (BIB) residues to the…

Time FactorsBioadhesivePharmaceutical ScienceCell LineDrug Delivery SystemsPolymethacrylic AcidsPolymer chemistryMucoadhesionCopolymerSide chainHumansPhea polybutylmethacrylate microparticles drug deliveryParticle SizeGlucocorticoidsDrug CarriersDose-Response Relationship DrugChemistryAtom-transfer radical-polymerizationBeclomethasoneAdhesivenessAndrogen AntagonistsGraftingFlutamideMicrospheresPolymerizationDelayed-Action PreparationsEmulsionSolventsNanoparticlesEmulsionsCaco-2 CellsPeptidesHydrophobic and Hydrophilic InteractionsInternational journal of pharmaceutics
researchProduct

Beclomethasone dipropionate and formoterol reduce oxidative/nitrosative stress generated by cigarette smoke extracts and IL-17A in human bronchial ep…

2013

Interleukin-17A (IL-17A), cigarette smoke and oxidative/nitrosative stress are involved in inflammatory airway diseases, and the mechanisms behind these processes are still poorly understood. We investigated whether recombinant human IL-17A (rhIL-17A), in combination with cigarette smoke extracts (CSE), increases the levels of inducibile nitric oxide synthase (iNOS), reactive oxygen species, nitrotyrosine (NT) and the activation of signal transducer and activator of transcription 1 (STAT-1) in normal human bronchial epithelial cells (16HBE). The effect of beclomethasone dipropionate (BDP), formoterol and their combination was also evaluated. We demonstrated that rhIL-17A or CSE alone increa…

Transcription GeneticNitric Oxide Synthase Type IIBronchiOxidative phosphorylationPharmacologyGene Expression Regulation EnzymologicCell Linechemistry.chemical_compoundFormoterol FumarateSmokeNitrilesmedicineButadienesGene silencingHumansGene SilencingPromoter Regions GeneticPharmacologychemistry.chemical_classificationReactive oxygen speciesbiologyNitrotyrosineInterleukin-17BeclomethasoneEpithelial CellsTobacco ProductsReactive Nitrogen SpeciesNitric oxide synthaseOxidative StressSTAT1 Transcription FactorchemistryEthanolaminesImmunologySTAT proteinbiology.proteinPhosphorylationFormoterolBiomarkersmedicine.drugEuropean journal of pharmacology
researchProduct

Photocrosslinking of dextran and polyaspartamide derivatives: a combination suitable for colon-specific drug delivery.

2007

Abstract The aim of this study was to prepare and characterize novel hydrogels with polysaccharide–polyaminoacid structure, able to undergo an enzymatic hydrolysis in the colon and potentially useful for treating inflammatory bowel diseases (IBD). Starting materials were methacrylated dextran (DEX-MA) and methacrylated α,β-poly(N-2-hydroxyethyl)- dl -aspartamide (PHM). These polymers were photocrosslinked by exposure of their aqueous solutions at 313 nm without photoinitiators. Different samples, shaped as microparticles, were obtained as a function of polymer concentration and irradiation time. FT-IR analysis confirmed the occurrence of a co-crosslinking between DEX-MA and PHM in all exper…

alpha; beta-poly(n-2-hydroxyethyl)-dl-aspartamide; biodegradable hydrogels; colon drug delivery; dextran; photocrosslinking; α; β-poly(n-2-hydroxyethyl)-dl-aspartamidealphaCell SurvivalColonPhotochemistryDrug CompoundingαPharmaceutical ScienceDosage formchemistry.chemical_compoundDrug StabilityEnzymatic hydrolysismedicineCell AdhesionOrganic chemistryHumansParticle Sizeβ-poly(n-2-hydroxyethyl)-dl-aspartamideDrug CarriersChromatographyDextranaseAqueous solutionChemistryHydrolysisbiodegradable hydrogelstechnology industry and agriculturecolon drug deliveryBeclomethasoneMucinsDextransHydrogelsHydrogen-Ion ConcentrationDextranCross-Linking Reagentsbeta-poly(n-2-hydroxyethyl)-dl-aspartamidedextranDrug deliverySelf-healing hydrogelsMethacrylatesSwellingmedicine.symptomphotocrosslinkingCaco-2 CellsPeptidesJournal of controlled release : official journal of the Controlled Release Society
researchProduct